摘要
目的评价艾迪注射液联合CHOP方案化疗治疗恶性淋巴瘤临床疗效和安全性。方法计算机检索C0chrane图书馆。Medine，EMbase，中国期刊全文数据库（CKNI），维普中文期刊，万方数据知识服务平台和中文科技全文数据库。纳入研究注明为有关艾迪注射液联合CHOP方案化疗治疗恶性淋巴瘤的临床随机对照试验（RCTs），对纳入的研究进行方法学质量评价，并使用RevMan5．2软件进行统计分析。结果共纳入7个RCTs，所有研究均未提及分配隐藏、盲法及失访。Meta分析结果显示，与单纯CHOP方案化疗相比，艾迪注射液联合CHOP方案化疗可以改善近期疗效（OR=1．67，95％CI：1．04～2．69），提高生活质量（OR=2．94，95％CI：1．78～4．86），减少白细胞下降（OR=0．24，95％CI：0．15～0．38）和血小板下降（OR=0．32．95％CI：0．20～0．53），降低胃肠道反应（OR=0．48，95％CI：0．28～0．83）。结论艾迪注射液联合CHOP方案化疗在提高有效率及生活质量方面更具优势，并显著降低化疗毒副作用发生率。
AIM To access the efficacy and safety of Aidi injection treatment combining CHOP chemotherapy for patients with malignant lymphoma. METHODS Randomized controlled trials （RCTs）, which focused on treating patients with malignant lymphoma using Aidi injection combining CHOP chemotherapy were identified from Cochrane library, Medline, EMbase, CNKI database, VIP database, Wanfang database and Chinese periodical full text database of science and technology. All of the included studies have been evaluated by quality assessment. RevMan 5.2 software was used for data analysis. RESULTS Seven RCTs were included in this review, all of studies did not mention allocation concealment, blind and information of loss to follow-up. Meta analysis results suggested that compared with CHOP alone, the combination therapy had statistically significant benefits in recent efficacy （OR = 1.67, 95%CI： 1.04 - 2.69）, improving quality of life （OR = 2.94, 95%CI： 1.78 - 4.86）, reduce white blood cells （OR = 0.24, 95%CI： 0.15 - 0.38） and platelets （OR = 0.32, 95%CI： 0.20 - 0.53） decline, and in reducing the gastrointestinal reaction （OR = 0.48, 95% CI： 0.28 - 0.83）. CONCLUSION Aidi injection combined with CHOP chemotherapy have significant therapy value in improving the recent efficiency rate and quality of life improvement rate, and significantly reduce the incidence of side effects of chemotherapy.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2014年第11期807-812,共6页
Chinese Journal of New Drugs and Clinical Remedies
